New Trends in Dual 5-LOX / COX Inhibition

By  

Current Medicinal Chemistry, Vol. 9, Iss. 9, 2002-05 ,pp. : 941-962

Bentham Science Publishers

Access to resources Recommend Favorite

Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors

By de Gaetano G.   Donati M.B.   Cerletti C.  

Trends in Pharmacological Sciences, Vol. 24, Iss. 5, 2003-05 ,pp. : 245-252

Elsevier

Access to resources Recommend Favorite

Cyclooxygenase-1/2 (COX-1/COX-2) and 5-lipoxygenase (5-LOX) inhibitors of the 6,7-diaryl-2,3-1H-dihydropyrrolizine type

By Ulbrich H.   Fiebich B.   Dannhardt G.  

European Journal of Medicinal Chemistry, Vol. 37, Iss. 12, 2002-12 ,pp. : 953-959

Elsevier

Access to resources Recommend Favorite

Dual COX-Inhibitors: The Answer is NO?

By  

Current Topics in Medicinal Chemistry, Vol. 5, Iss. 5, 2005-06 ,pp. : 487-492

Bentham Science Publishers

Access to resources Recommend Favorite

Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs

By Charlier C.   Michaux C.  

European Journal of Medicinal Chemistry, Vol. 38, Iss. 7, 2003-07 ,pp. : 645-659

Elsevier

Access to resources Recommend Favorite